Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Suk-young | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.date.accessioned | 2021-12-24T01:41:00Z | - |
dc.date.available | 2021-12-24T01:41:00Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/132713 | - |
dc.description.abstract | Despite being one of the most frequently diagnosed cancers worldwide, prognosis of metastatic colorectal cancer (CRC) was poor. Development and introduction of biologic agents in treatment of patients with metastatic CRC have brought improved outcomes. Monoclonal antibodies directing epidermal growth factor receptors and vascular endothelial growth factor are main biologic agents currently used in treatment of metastatic CRC. Encouraged by results from many clinical trials demonstrating efficacy of those monoclonal antibodies, the combination therapy with those targeted agents and conventional chemotherapeutic agents has been established as the standard therapy for patients with metastatic CRC. However, emergency of resistance to those target agents has limited the efficacy of treatment, and strategies to overcome the resistance are now being investigated by newly developed biological techniques clarifying how to acquire resistance. Here, we introduce mechanisms of action of the biologic agents currently used for treatment of metastatic CRC and several landmark historical clinical studies which have changed the main stream of treatment. The mechanism of resistance to those agents, one of serious problems in treatment metastatic CRC, and ongoing clinical trials to overcome the limitations and improve treatment outcomes will also be presented in this review. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI LTD | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | CETUXIMAB PLUS IRINOTECAN | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | KRAS WILD-TYPE | - |
dc.subject | K-RAS MUTATIONS | - |
dc.subject | FACTOR RECEPTOR | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | OPEN-LABEL | - |
dc.subject | RANDOMIZED PHASE-3 | - |
dc.subject | BRAF MUTATION | - |
dc.title | Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.1155/2016/7590245 | - |
dc.identifier.scopusid | 2-s2.0-84965098609 | - |
dc.identifier.wosid | 000374394500001 | - |
dc.identifier.bibliographicCitation | BIOMED RESEARCH INTERNATIONAL, v.2016 | - |
dc.relation.isPartOf | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.title | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.volume | 2016 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | CETUXIMAB PLUS IRINOTECAN | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | KRAS WILD-TYPE | - |
dc.subject.keywordPlus | K-RAS MUTATIONS | - |
dc.subject.keywordPlus | FACTOR RECEPTOR | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-3 | - |
dc.subject.keywordPlus | BRAF MUTATION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.